Ambrx to receive milestone payment from BristolMyers Squibb for the initiation of Phase 1 Clinical Trial of a longacting Relaxin derivative

Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative

04:49 EDT 18 Jul 2019 | Synbiobeta

– Long acting Relaxin is powered by Ambrx technology SAN DIEGO, California, July 16, 2019 –Ambrx Inc, today announced that Bristol-Myers Squibb Company (“BMS”) has initiated a phase I clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of long-acting Relaxin for the potential treatment of heart failure (“HF”). Long-acting Relaxin is an investigational biologic […]

More From BioPortfolio on "Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative"